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Abstract 
Two patients with chronic cervical spinal 
cord injury and quadriplegia underwent 
partial resection of the medular scar and 
implant of bone marrow tissue with a  
combination  of drugs at the site of spinal 
cord injury. Post-operatively they received a 
similar treatment in the neuromotor 
rehabilitation centre and were treated 
additionally with cerebrolysin . Sensory 
improvements were noticed, but no 
significant motor improvements were 
observed twenty months afterwards.  
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Spinal cord injury (SCI) is a major 
medical problem worldwide and cervical 
spinal cord injuries can lead to quadriplegia 
and have devastating consequences for 
victims, families, and society in general. 
Today there are no fully restorative 
treatments for spinal cord injury, but 
various cellular therapies have been tested 
in animal models. During the spinal cord 
injury there is a complete or an incomplete 
section; therefore there is a disrupted spinal 
cord or some types of contusion, 
compression, penetration or laceration of 
the spinal cord occur. Spinal cord injury 
culminates in glial scarring, a multifactorial 
process that involves reactive astrocytes, 
microglia and macrophages, fibroblasts and 
Schwann cells.(3,4,8,9) 
The scar is often oriented 
perpendicularly to the neuraxis and appears 
impenetrable. The scar also contains 
molecular inhibitors of axon growth. 
Progressive expansion of the injury across 
more than one segment can also occur over 
months or years. Therefore after spinal cord 
injury there are two types of lesions : 
complete disruption of the spinal cord or 
different types of scars.  
The scar of the spinal cord can be:  
- a complete and impenetrable glial scar 
on the site of spinal cord injury, 
- an incomplete scar and a post-
traumatic syringomyelia or post-traumatic 
cysts on the site of spinal cord injury,  
- a filiform connective scar of the two 
segments of damaged spinal cord. 
The glial scar, which is rich in growth 
inhibitors, as chondroitin sulfate 
proteoglycan (CSPG), is a major 
impediment to axonal regeneration 
following injury.  
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The inability to repair spinal cord 
damage is attributed to several factors: 
• the presence of inhibitory substances 
in the tissue that surrounds the lesion,  
• changes inside adult nerve fibres that 
make them unable to respond well to 
growth-inducing signals, 
• the formation of cysts at the injury site 
which growing fibres cannot cross,  
• the lack of  nerve growth factors at the 
injury site, 
• the formation of scar tissue at the 
injury site with additional inhibitory 
substances. 
Therefore any treatment must solve the 
above difficult problems.(7,13,14)  
There are no fully restorative treatments 
for spinal cord injury, but various 
rehabilitative therapies have been tested on 
animal models to improve functional 
outcomes after spinal cord injury. The stem 
cells based therapies are being tried in order 
to repair or replace tissues or cells damaged 
by injuries or diseases and to treat serious 
chronic diseases, such as spinal cord 
injuries. 
Three therapeutic concepts are currently 
being envisaged: 
1. Transplantation of differentiated cells 
derived from stem cells. The source for the 
specific differentiated cell types could be 
embryonic or somatic stem cells including 
the patient’s own stem cells. 
2. Direct administration of stem cells 
directly to the patient; the stem cells will 
differentiate into the desired cell type . 
3. Stimulation of endogenous stem cells, 
induced by stimulating an individual’s own 
population of stem cells by administrating 
growth factors. 
Stem cells are feasible candidates for cell 
therapy of spinal cord injury. (8,10,15) 
Bone marrow cells are the subject of 
extensive interest because of their stem cell 
like characteristics and pluripotency. 
(11,16,18)  
There are more data supporting the 
beneficial effects of bone marrow cells in 
SCI: 
1. bone marrow contains multipotent 
adult progenitor cells that produce a variety 
of cell types, including neuroectodermal, 
mesodermal and endodermal cell types. 
2. bone marrow cell transplants improve 
function recovery and differentiate into 
astrocytes, oligodendroglia and neural 
presursors in animal experiments. 
3. bone marrow cell transplants facilitate 
remyelination of the spinal cord, appear to 
be neuroprotective and also promote 
regeneration in injured animal spinal cords. 
(21,22,24,25) 
Neurotrophins and growth factors play 
an important role in development of the 
central nervous system and several 
neurotrophic factors induce 
neuroprotection in traumatic spinal cord 
injuries. (20) Understanding the 
mechanisms by which adult stem cells 
produce growth factors and the effect of 
components of the spinal cord injury milieu 
to stimulate growth factor production and 
to promote spinal cord lesion repair are 
very significant issues. 
A combination of stem cells therapy 
with neurotrophins  is a novel aspect of 
treatment in spinal cord injury and it will 
attenuate the neurological damage and 
could help restore the normal function of 
spinal cord.  
There are several similarities  between 
the traumatic brain injuries and spinal cord 
injuries and there are also some similarities 
between the both their treatments. 
Numerous studies have documented the 
neuroprotective and neurotrophic 
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properties of cerebrolysin in traumatic brain 
injury. Cerebrolysin is a standardized 
porcine brain-derived drug  and it can pass 
through the blood-brain barrier.  
This paper presents the experience of 
two patients with traumatic chronic cervical 
spinal cord injuries with quadriplegia and 
the results of the microsurgical resection of 
the spinal scar and the implant of bone-
marrow tissue in the site of the spinal cord 
lesion . 
Methods 
Two patients with chronic cervical spinal 
cord injury and quadriplegia voluntarily 
participated in this study. The cervical SCI 
events occurred at least two years before 
this study. Two physicians independently 
assessed the neurological injury status of 
each patient before and at regular intervals 
after the surgery. The surgical approaches 
and the implant were performed by the 
same neurosurgical team. The study 
protocol was approved by the Ethics 
Committee of the Hospital “Prof Dr 
Nicolae Oblu“, Iasi and the subjects gave 
informed consent. 
Each patient underwent a cervical 
laminectomy to expose the site of the 
cervical spinal cord injury and a 
microsurgical partial resection of the 
medular scar and implant of autologous 
bone marrow tissue with a combination of 
drugs at the site of spinal cord injury. 
(Figure 1) No post- surgery complications 
occurred.  
Post-operatively the patients received a 
similar treatment in the neuromotor 
rehabilitation centre, also they received 5 - 
10 mL/day for three to five months 
postoperatively. 
Results 
Two male patients were included in this 
study with the age of 26 and 33 years. 
Sensory improvements were noticed, but 
no significant motor improvements were 
observed twenty months afterwards.     
(Table 1). 
Discussion  
The mechanisms of spinal injury are 
very important for the type of lesion of the 
spinal cord. When the spinal cord is 
injured, a number of events occur : injury 
of the neurons ( broken neural cell 
membranes, cut axons), blood vessels 
disruption, bleeding in the central grey 
matter, spinal cord edema and 
hypoperfusion of the spinal cord, the dura 
mater injury. The spinal cord injury is a 
complete lesion - a disrupted spinal cord, or 
an incomplete lesion - different types of 
compression or laceration of the spinal 
cord. A dura mater sheath lesion is followed 
by a fibroblastic reaction in the epidural 
tissue extended into the spinal cord with a  
connective scar, but maintaining the dural 
continuity can limit the formation of 
connective tissue scarring in the epidural 
space. (7)  
 
 
No 
case 
Age 
F/M 
Cervical SCI level History 
of injury 
Neurology Cerebrolysin 
postoperatively 
Outcome 
(m = months) 
1 26 /M C4-C5     3y quadriplegia Yes ; 5 mL/day 
 3 months 
20  m : C7 
2 33 /M C5-C6    3y quadriplegia Yes ; 5 mL/day 
 3 months   
22  m : C8 
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The dural duraplasty following acute 
spinal cord laceration may improve 
cerebrospinal fluid flow by limiting 
meningeal fibrosis adjacent to the injury 
and minimize connective tissue scar 
formation. (9) 
The surgical treatment (ideally - within 
eight hours of the injury occuring) must 
remove the tissues causing spinal cord 
compression, must correct a gross 
misalignment and must stabilize the spine.  
Immediate surgery for spinal 
decompression including the duraplasty is 
of high importance for the prognosis and 
evolution of spinal cord injury.  
The secondary spinal cord injury is the 
damage that continues in the hours 
following trauma and consists of  reduction 
in blood flow at the level of injury, 
excessive release of neurotransmitters 
(glutamate), inflamatory response, free 
radicals attack neurons and neuronal 
apoptosis. During this delayed secondary 
spinal cord injury  the treatment may 
reduce the extent of disability, eg. 
methylprednisolone given within 8 hours 
of the injury occuring significantly 
improves recovery in humans. (2, 7,18,19)  
An efficient treatment in spinal cord 
lesions must combine several main 
approaches:  
- minimising the initial damage and 
protecting surviving neurons - 
neuroprotection, 
- removing barriers: after the injury the 
scar tissue gradually fills the damaged area 
and it is an impenetrable barrier and it does 
not allow regenerating nerve fibres to pass 
through. 
- blocking factors which inhibit neural 
regeneration,  
- modulation of inflammatory response 
following spinal cord injury, 
- preventing inhibition of regrowth, 
- tissue engineering:  biocompatible 
materials can form a bridge across the 
damaged region , 
- stimulating and guiding – neurotrophic 
factors, 
- replacing damaged cells – stem cells 
therapy, 
- correctly reconnecting the damaged 
neural circuits inside and outside the spinal 
cord 
Many researchers have tried to find 
effective strategies to improve outcomes 
after spinal cord injuries.(2,7,14,27,28) 
Substances that limit secondary injury 
processes and promote repair and 
regeneration of the injured spinal cord such 
as monosialotetrahexosylganglioside (GM-
1), 4-aminopyridine (4-AP), [a potassium-
channel blocking agent], brain derived 
neurotrophic factor (BDNF) and glial-
derived neurotrophic factor (GDNF), also 
inhibitors of Nogo (neurite outgrowth 
inhibitor) and MAG (myelin-associated 
glycoprotein), have been studied. Also 
transplanted tissues and cells, such as blood 
macrophages, bone marrow transplant with 
GM-CSF, olfactory ensheathing cells, fetal 
tissues, stem or progenitor cells, appear to 
produce neurological improvements.(11,29) 
In pathological conditions eg. spinal cord 
injury, the neurotrophins promote survival 
and rescue nerve cells from death and 
promote neurite extension, neuronal 
survival and differentiation. In spinal cord 
injury, the neurotrophins are able to 
enhance axonal regeneration and reduce 
paraplegia. (23,24,25,26) Some authors 
showed that the most efficient strategy for 
the acute complete transection of spinal 
cord was a combination of implantation of 
Schwann cells, plus neuroprotective agents 
and growth factors administered in various 
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ways, olfactory ensheathing cell (OEC) 
implantation and chondroitinase 
administration.(2,3) Other study concluded 
that combinations of interventions were 
needed to surmount the multiple barriers to 
recovery in spinal cord injury recovery.(20) 
Two small studies noted sensory 
improvements in SCI patients who 
underwent autologous bone marrow cell 
transplantation (BMT) in conjunction with 
granulocyte macrophage-colony stimulating 
factor (GM-CSF) administration. (12,17) 
Our study included two complete 
cervical SCI patients and bone-marrow 
tissue obtained from the patient was 
implanted in conjunction with cerebrolysin 
as neurotrophic factor. The surgical 
procedure consisted of microsurgical 
dissection and partial removal of the spinal 
cord scar and implanting of the bone-
marrow tissue into the spinal cord injury 
site. Sensory improvements were noticed, 
but no motor improvements were observed 
twenty months afterwards. There are only 
few studies of the effect of cerebrolysin in 
nerve and spinal cord injuries in animal 
models (1,5,6) and a comparison of the 
efficacy of brain-derived neurotrophic 
factor (BDNF) and cerebrolysin treatment 
demonstrated that BDNF has more modest 
effects in functional recovery than 
cerebrolysin in nerve injury.(6) Our results 
show that the cerebrolysin acted as a 
neurotrophic factor after the bone marrow 
implant and it was clinically effective in the 
long term treatment of one patient with 
chronic traumatic spinal cord injury. 
Conclusion 
This is a preliminary study of the 
autologous bone marrow tissue implant 
into the lesioned cervical spinal cord and 
there are only two cases, but it is the first 
study about cerebrolysin in human cases of 
traumatic chronic cervical spinal cord 
injury. The bone-marrow tissue 
transplantation procedure has no 
complications. The post - injury scar’s 
microsurgical partial removement may 
make the injury site more permeable to the 
axons attempting to re-grow through. This 
result is promising, but much follow-up 
work is needed to document the long-term 
benefits. 
The results are modest - like everywhere 
else, yet - but promising, compared to the 
lack of any effective therapeutic alternative. 
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